Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
National Cancer Institute (NCI)
AstraZeneca
Mayo Clinic
STORM Therapeutics LTD
Pfizer
Eastern Cooperative Oncology Group
Neonc Technologies, Inc.
ViroMissile, Inc.
Ipsen
Bristol-Myers Squibb
AstraZeneca
Washington University School of Medicine
Radiopharm Theranostics, Ltd
Arvinas Inc.
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
Genentech, Inc.
DualityBio Inc.
MacroGenics
Alliance for Clinical Trials in Oncology
Pfizer
Daiichi Sankyo
University of Nebraska
Elephas
Innate Pharma
The Netherlands Cancer Institute
Elephas
OncoNano Medicine, Inc.
Compass Therapeutics
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Cancer Research UK
LG Chem
West China Hospital
DualityBio Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Travera Inc
Memgen, Inc.
Guardant Health, Inc.
Azienda Ospedaliera di Padova
Marengo Therapeutics, Inc.
Iovance Biotherapeutics, Inc.
UNICANCER
Rapa Therapeutics LLC
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University Medical Center Groningen
Vyriad, Inc.